Mizuho raised the firm’s price target on Encompass Health to $95 from $93 and keeps a Buy rating on the shares. The company reported one of the strongest quarters in its history with an all-around beat, the analyst tells investors in a research note. Given the strong fundamentals in the inpatient rehabilitation business, continued improvement in labor trends, bed expansion strategy, and acquisitions, the firm continues to believe the visibility is strong for Encompass.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EHC:
- Encompass Health Enhances Investor Insights with Adjusted Financials
- Encompass Health reports results for first quarter 2024
- Encompass Health (EHC) Q1 Earnings Cheat Sheet
- Encompass Health to build 50-bed rehabilitation hospital in San Antonio
- Encompass Health price target raised to $101 from $95 at Barclays